FH
Foghorn Therapeutics Inc.
FHTX · NASDAQ
$4.67 -1.89% (-$0.09)
1M -22.60%
Market Cap $283.6M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
8 /100
Expensive P/S 7.72x
P/E N/A
EV/EBITDA N/A
Growth
96 /100
Growing Rev. growth 17.14%
EPS growth N/A
FCF growth N/A
Profitability
17 /100
Weak Gross margin 42.73%
Net margin 175.78%
FCF margin 232.31%
Quality
3 /100
Poor ROIC 44.00%
ROA 31.75%
Asset turnover 0.18x
Debt
100 /100
Low Current ratio 3.36x
Debt/Equity N/A
Int. coverage N/A
Stability
31 /100
Unstable Beta 2.86x
Rev. volatility 56.38%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o FHTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Adrian H. Gottschalk
Employees
106
Headquarters
Watertown
Prihajajoči dogodki
04 NOV.
Earnings
Upcoming earnings report